ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

ClinicalTrials.gov ID: NCT01769508

Public ClinicalTrials.gov record NCT01769508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study With Lead-in Safety Cohort of 5-Fluorouracil, Oxaliplatin and Lapatinib in Combination With Radiation Therapy as Neoadjuvant Treatment for Patients With Localized HER2 Positive Esophagogastric Adenocarcinomas

Study identification

NCT ID
NCT01769508
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
SCRI Development Innovations, LLC
Other
Enrollment
12 participants

Conditions and interventions

Interventions

  • 5-Fluorouracil Drug
  • Lapatinib Drug
  • Oxaliplatin Drug
  • Radiation Therapy Radiation

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2013
Primary completion
Jan 31, 2014
Completion
Jan 31, 2015
Last update posted
Jun 12, 2016

2013 – 2015

United States locations

U.S. sites
9
U.S. states
5
U.S. cities
9
Facility City State ZIP Site status
Florida Cancer Specialists - South Fort Myers Florida 33916
Florida Hospital Cancer Institute Orlando Florida 32804
Woodlands Medical Specialists Pensacola Florida 32503
Florida Cancer Specialists-North St. Petersburg Florida 33705
Northeast Georgia Medical Center Gainesville Georgia 30501
Grand Rapids Oncology Program Grand Rapids Michigan 49503
Oncology Hematology Care Cincinnati Ohio 45242
Chattanooga Oncology and Hematology Associates Chattanooga Tennessee 37404
Tennessee Oncology Nashville Tennessee 37203

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01769508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 12, 2016 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01769508 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →